Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Percutaneous Vascular Interventions for Acute Ischemic Stroke
Stroke 42:e31-e32, ORourke,K.,et al, 2011
Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity
Thromb Hemost 103:1116-1127, van Ryn,J.,et al, 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
The Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for the Prevention of Venous Thromboembolism After Acute Ischaemic Stroke (PREVAIL Study): An Open-Label Randomised Comparison
Lancet 369:1347-1355, Sherman,D.G.,et al, 2007
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004
Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Spinal and Epidural Hematoma and Low-Molecular-Weight Heparin
NEJM 338:1774-1775, Wysowski,D.K.,et al, 1998
Anticoagulation Therapy in Pediatric Patients with Sinovenous Thrombosis,A Cohort Study
Arch Neurol 55:1533-1537, deVeber,G.,et al, 1998
Epidural/Spinal Hematoma with Low Molecular Weight Heparin & Spinal/Epidural Anesth or Spinal Puncture
FDA Advisory, Dec 151997., , 1997
Spectrum of Intracranial Hemorrhages in Cerebral Venous Thrombosis, A Pictorial Case Series and Review of Pathophysiology and Management
Neurologist 30:45-51, Jha,S.,et al, 2025
Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025
Anticoagulation or Antiplatelet Therapy for Device-Detected Atrial Fibrillation
NEJM 392:1749-1751, Gorey,S., 2025
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
JAMA Neurol 81:1150-1158, Maarse,M.,et al, 2024
2024 Guide for the Primary Prevention of Stroke:A Guideline From the American Heart Association/American Stroke Association
Stroke 55:e344-e424, Bushnell,C.,et al, 2024
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage
JAMA Neurol 8:363-372, Sheth,K.M.,et al, 2024
Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Replacement:A Review
Stroke 55:2754-2764, Patel,K.P.,et al, 2024
Anticoagulation vs Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source
Neurol 103:e209949, Grannam,M.,et al, 2024
Timing of Anticoagulation Resumption and Risk of Ischemic and Hemorrhagic Complications in Patients with ICH and Mechanical Heart Valves
Neurol 103:e209664, Sakusic,A.,et al, 2024
Recurrent Ischemic Stroke in Patients with Atrial Fibrillation Whle Receiving Oral Anticoagulants
JAMA Neurol 81:805-813, Hindsholm,M.F.,et al, 2024
Perioperative Acute Ischemic Stroke in Patients with Atrial Fibrillation
Ann Neurol 94:321-329, Shu,L.et al, 2023
Coagulation Factor Expression and Composition of Arterial Thrombi in Cancer-Associated Stroke
Stroke 54:2981-2989, Yoo,J.,et al, 2023
Clinicopathologic Conference, Antiphospholipid Syndrome due to SLE with Hypocomplimentemia
NEJM 389: 2277-2285, Case 38-2023, 2023
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction
Stroke 54:1954-1959, Bilski.A.,et al, 2023
Antithrombotic Therapy in Patients with Cerebral Microbleeds or Cortical Siderosis, Is This Contraindicated?
Neurol 100:551-552, Schneck,M.J., &Biller,J., 2023
A 25-Year-Old Woman With Eye Swelling and HEadache
Neurol 100:879-883, Hehir,A.,et al, 2023
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Cortical Superficial Siderosis and Transient Focal Neurological Episode Preceding Lobar Hemorrhage in Cerebral Amyloid Angiopathy
Stroke 54:e48-e51, Therdorou,A.,et al, 2023
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Anticoagulants for Acute Ischemic Stroke: Cochrane Review
Stroke 53:e385-e387, Wang, X.,et al, 2022
Contemporary Trends in the Nationwide Incidence of Primary Intracerebral Hemorrhage
Stroke 53:e70-e74, Bako, A.T.,et al, 2022
Endovascular Therapy Versus Anticoagulation for Treatment of Cerebral Venous Sinus Thrombosis
Neurologist 27:69-73, Xu, Z.,et al, 2022
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Clinicopathological Conference, Systemic Lupus Erythematosus with Antiphospholipid Syndrome
NEJM 386:1560-1570, Case 12-2022, 2022